The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout

Nature Reviews Rheumatology, Published online: 12 March 2024; doi:10.1038/s41584-024-01092-xGout is associated with various cardiometabolic–renal comorbidities that increase the risk of mortality. Sodium–glucose cotransporter type 2 (SGLT2) inhibitors show promise in both addressing the symptoms of gout and managing relevant comorbidities to help prevent premature mortality.

Source: Nature Reviews Rheumatology - March 12, 2024 Category: Rheumatology Authors: Chio Yokose Natalie McCormick Abhishek Abhishek Nicola Dalbeth Tristan Pascart Fr édéric Lioté Angelo Gaffo John FitzGerald Robert Terkeltaub Meghan E. Sise James L. Januzzi Deborah J. Wexler Hyon K. Choi Source Type: research